Zhejiang Anglikang Pharmaceutical Co Ltd Class A

Zhejiang Anglikang Pharmaceutical Co., Ltd. announced on August 24, 2026 that its mosapride citrate active pharmaceutical ingredient has received the chemical API marketing application approval notice issued by the National Medical Products Administration. The API is used for the company's mosapride citrate tablets, which have entered the registration application stage and are mainly used to improve symptoms such as heartburn, belching, nausea, vomiting, early satiety, upper abdominal distension, and upper abdominal pain caused by weakened gastrointestinal motility. Besides the company, 12 domestic enterprises currently have registration status A. The company submitted its registration application in October 2024, was accepted in the same month, and recently received approval. The company said this approval will further enrich its product line and enhance its core competitiveness, while also noting that competition in this API market is relatively fierce, and that drug research and development, production, and sales are subject to significant uncertainty due to national policies, market conditions, and other factors.

Anglikang announced that it has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch issued by the National Medical Products Administration. The drug is used for anti-inflammatory and analgesic treatment of conditions and symptoms such as osteoarthritis, muscle pain, and swelling and pain after trauma.

Anglikang announced that it plans to invest 50 million yuan of its own funds in three phases to increase capital in Shengruikang Biomedical Hangzhou Company Limited, acquiring a total of 36.4706 percent equity in Shengruikang. After the capital increase is completed, Anglikang will also obtain priority cooperation rights for Shengruikang's research and development products in the Greater China region.